preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Doctors Rely on More than Just Data for …

Many technology companies are working on artificial intelligence systems that can analyze medical data to help diagnose or treat health problems. Such systems raise the question of whether this kind...

App, Brief Intervention may be Lifesaver…

A troubled teenager is hospitalized with suicidal thoughts. The patient is diagnosed, medicated, and counseled by a team of experts. The teen is sent home a few days later, and...

New Coalition of Philanthropists Includi…

Philanthropist Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder have announced a new initiative, Diagnostics Accelerator, to develop novel biomarkers for the early detection of Alzheimer's...

IMI Launches New Antimicrobial Resistanc…

A new Antimicrobial Resistance (AMR) Accelerator Programme is part of new Calls for proposals launched today by the Innovative Medicines Initiative (IMI). Of the other topics launched in the Calls...

Wearable Devices and Mobile Health Techn…

With increasing efforts being made to address the current global obesity epidemic, wearable devices and mobile health ("mHealth") technology have emerged as promising tools for promoting physical activity. However, current...

Frontiers Health 2018

15 - 16 November 2018, Berlin, Germany. Frontiers Health has fast become one of the premiere conferences in the digital health space, combining a unique mix of attendees and presenters from...

Digital Health to Disrupt Health IT Mark…

25 - 26 March 2019, London, United Kingdom. Digital Health - publishers of digitalhealth.net and organisers of the CCIO, CNIO, CIO Networks and annual Summer Schools - is to shake up...

Bayer Cares Foundation Promotes Sustaina…

Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim...

Philips and Oxford University Hospitals …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Oxford University Hospitals (OUH) NHS Foundation Trust, announced plans to create a digital pathology network to help...

Maidstone and Tunbridge Wells NHS Trust …

Maidstone and Tunbridge Wells NHS Trust has selected Allscripts Sunrise as its electronic health record, in a move that further solidifies the company's position in the South East of England...

Start Alliance Berlin: Digital Health

Start Alliance Berlin: Digital Health is a two-week program taking place in November 2018 which is intended to help startups from BEIJING, DUBAI, NEW YORK, LONDON, PARIS, SHANGHAI, TEL AVIV...